Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c
NCT06365216 is registered in ClinicalTrials.gov with Axoltis Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c
- Lead sponsor
- Axoltis Pharma
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 25, 2024
- Completion date
- September 30, 2026
- Enrollment
- 80 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.